Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor
The SNR CAR-T cell approach addresses tumor antigen heterogeneity and suppressive tumor microenvironment, offering a promising therapeutic strategy for solid tumors and paving the way for its future clinical applications.
Authors
- Hongye Wang (ORCID: https://orcid.org/0000-0002-6467-0316)
- Minmin Sun (ORCID: https://orcid.org/0000-0002-2163-7188)
- Xin Liu (ORCID: https://orcid.org/0009-0007-4110-6900)
- Xuemei Zhang (ORCID: https://orcid.org/0000-0002-4979-6965)
- Yantao Li (ORCID: https://orcid.org/0000-0001-7545-1883)
- Hong Xin (ORCID: https://orcid.org/0000-0001-9155-4217)
- Zhaorong Wu (ORCID: https://orcid.org/0000-0003-1897-1721)
- Ruidong Hao (ORCID: https://orcid.org/0009-0000-7319-3657)
- Yuanguo Cheng
- Linke Bian
- Bo Zhai (ORCID: https://orcid.org/0000-0001-7055-3768)
- Shuangshuang Zhang (ORCID: https://orcid.org/0009-0005-7521-0867)
Institutions
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Renji Hospital (CN)
- Shanghai Cancer Institute (CN)
- Shanghai East Hospital (CN)
- State Key Laboratory of Oncogene and Related Genes (CN)
- Viva Biotech (China) (CN)
- Shanghai Institute of Pharmaceutical Industry (CN)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1007/s13402-025-01066-5
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- Yuhan